Cargando…
Coadministration of Cyclosporin A with Prednisolone in Acute Interstitial Pneumonia Complicating Polymyositis/Dermatomyositis
OBJECTIVE: To investigate clinical effectiveness of prednisolone (PSL) and cyclosporin A (CyA), particularly continuous intravenous administration of the latter, in patients with interstitial pneumonia (IP) associated with polymyositis/dermatomyositis (PM/DM). METHODS: We reviewed the clinical findi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308719/ https://www.ncbi.nlm.nih.gov/pubmed/22442637 http://dx.doi.org/10.4137/CMAMD.S9398 |
_version_ | 1782227448624054272 |
---|---|
author | Shimojima, Yasuhiro Ishii, Wataru Matsuda, Masayuki Katoh, Nagaaki Tazawa, Ko-ichi Sekijima, Yoshiki Ikeda, Shu-ichi |
author_facet | Shimojima, Yasuhiro Ishii, Wataru Matsuda, Masayuki Katoh, Nagaaki Tazawa, Ko-ichi Sekijima, Yoshiki Ikeda, Shu-ichi |
author_sort | Shimojima, Yasuhiro |
collection | PubMed |
description | OBJECTIVE: To investigate clinical effectiveness of prednisolone (PSL) and cyclosporin A (CyA), particularly continuous intravenous administration of the latter, in patients with interstitial pneumonia (IP) associated with polymyositis/dermatomyositis (PM/DM). METHODS: We reviewed the clinical findings and therapeutic outcomes of patients with PM/DM who had received PSL and CyA (PSL + CyA, n = 21 for DM and 2 for PM) or the former alone (n = 12 for DM and 7 for PM). All patients receiving PSL + CyA had active IP. RESULTS: Fifteen of the 21 DM patients receiving PSL + CyA showed favorable therapeutic outcomes of IP (recovery group), while the remaining 6 died of respiratory failure (death group). Before treatment PaO(2) in room air and %VC were significantly lower, and the total CT score was significantly higher in the death group than in the recovery one. Continuous intravenous administration of CyA was performed in 6 patients for severe IP requiring oxygen therapy, and of these 2 showed complete recovery from it. CONCLUSIONS: Coadministration of PSL and CyA, particularly continuous intravenous infusion of the latter, from the early phase of illness may be a potent therapeutic option for PM/DM patients with decreases in PaO(2) and %VC and/or a high total CT score suggestive of a poor prognosis. |
format | Online Article Text |
id | pubmed-3308719 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-33087192012-03-22 Coadministration of Cyclosporin A with Prednisolone in Acute Interstitial Pneumonia Complicating Polymyositis/Dermatomyositis Shimojima, Yasuhiro Ishii, Wataru Matsuda, Masayuki Katoh, Nagaaki Tazawa, Ko-ichi Sekijima, Yoshiki Ikeda, Shu-ichi Clin Med Insights Arthritis Musculoskelet Disord Original Research OBJECTIVE: To investigate clinical effectiveness of prednisolone (PSL) and cyclosporin A (CyA), particularly continuous intravenous administration of the latter, in patients with interstitial pneumonia (IP) associated with polymyositis/dermatomyositis (PM/DM). METHODS: We reviewed the clinical findings and therapeutic outcomes of patients with PM/DM who had received PSL and CyA (PSL + CyA, n = 21 for DM and 2 for PM) or the former alone (n = 12 for DM and 7 for PM). All patients receiving PSL + CyA had active IP. RESULTS: Fifteen of the 21 DM patients receiving PSL + CyA showed favorable therapeutic outcomes of IP (recovery group), while the remaining 6 died of respiratory failure (death group). Before treatment PaO(2) in room air and %VC were significantly lower, and the total CT score was significantly higher in the death group than in the recovery one. Continuous intravenous administration of CyA was performed in 6 patients for severe IP requiring oxygen therapy, and of these 2 showed complete recovery from it. CONCLUSIONS: Coadministration of PSL and CyA, particularly continuous intravenous infusion of the latter, from the early phase of illness may be a potent therapeutic option for PM/DM patients with decreases in PaO(2) and %VC and/or a high total CT score suggestive of a poor prognosis. Libertas Academica 2012-03-14 /pmc/articles/PMC3308719/ /pubmed/22442637 http://dx.doi.org/10.4137/CMAMD.S9398 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. |
spellingShingle | Original Research Shimojima, Yasuhiro Ishii, Wataru Matsuda, Masayuki Katoh, Nagaaki Tazawa, Ko-ichi Sekijima, Yoshiki Ikeda, Shu-ichi Coadministration of Cyclosporin A with Prednisolone in Acute Interstitial Pneumonia Complicating Polymyositis/Dermatomyositis |
title | Coadministration of Cyclosporin A with Prednisolone in Acute Interstitial Pneumonia Complicating Polymyositis/Dermatomyositis |
title_full | Coadministration of Cyclosporin A with Prednisolone in Acute Interstitial Pneumonia Complicating Polymyositis/Dermatomyositis |
title_fullStr | Coadministration of Cyclosporin A with Prednisolone in Acute Interstitial Pneumonia Complicating Polymyositis/Dermatomyositis |
title_full_unstemmed | Coadministration of Cyclosporin A with Prednisolone in Acute Interstitial Pneumonia Complicating Polymyositis/Dermatomyositis |
title_short | Coadministration of Cyclosporin A with Prednisolone in Acute Interstitial Pneumonia Complicating Polymyositis/Dermatomyositis |
title_sort | coadministration of cyclosporin a with prednisolone in acute interstitial pneumonia complicating polymyositis/dermatomyositis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308719/ https://www.ncbi.nlm.nih.gov/pubmed/22442637 http://dx.doi.org/10.4137/CMAMD.S9398 |
work_keys_str_mv | AT shimojimayasuhiro coadministrationofcyclosporinawithprednisoloneinacuteinterstitialpneumoniacomplicatingpolymyositisdermatomyositis AT ishiiwataru coadministrationofcyclosporinawithprednisoloneinacuteinterstitialpneumoniacomplicatingpolymyositisdermatomyositis AT matsudamasayuki coadministrationofcyclosporinawithprednisoloneinacuteinterstitialpneumoniacomplicatingpolymyositisdermatomyositis AT katohnagaaki coadministrationofcyclosporinawithprednisoloneinacuteinterstitialpneumoniacomplicatingpolymyositisdermatomyositis AT tazawakoichi coadministrationofcyclosporinawithprednisoloneinacuteinterstitialpneumoniacomplicatingpolymyositisdermatomyositis AT sekijimayoshiki coadministrationofcyclosporinawithprednisoloneinacuteinterstitialpneumoniacomplicatingpolymyositisdermatomyositis AT ikedashuichi coadministrationofcyclosporinawithprednisoloneinacuteinterstitialpneumoniacomplicatingpolymyositisdermatomyositis |